Clinical Trial

A Nine Week Open-Label Crossover Study of Insulin Degludec (U100 and U200) and Insulin Glargine (U300) to Observe and Compare the Incidence of Hypoglycemia when Basal Insulin Administration is Changed from Evening to Morning.

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The primary objective of this study is to observe a small sample size of patients with type 2 diabetes mellitus using insulin glargine (300 units/ml), insulin degludec (100 units/ml), and insulin degludec (200 units/ml) for the incidence and severity of hypoglycemia events from evening administration of basal insulin versus morning administration of basal insulin.

Information

Principal Investigator Marcel Twahirwa, MD
Co-PI
Sponsor
Type of Trial Prospective/Interventional